Check Before the Market Open (ILMN, CLWR, FSLR, MAKO)

Los Angelas, CA -- (SBWIRE) -- 01/08/2013 -- Shares of Illumina (NASDAQ:ILMN) were off as much as 10 percent on Monday morning before losses settled to about 6 percent in the early afternoon. Investors are pulling back after Roche Holding chairman Franz Humer confirmed that Illumina is “definitely off the table” as an acquisition target. Roche is a Swiss company that operates in pharmaceuticals and diagnostics worldwide. Illumina develops and manufactures DNA sequencing machines that are used to diagnose rare diseases and genetic conditions. Illumina, relatively small with a market cap of about $6.3 billion, was a natural target for Roche, which has a market cap of about $174 billion.

Are These Stock Buy or Sell? Get a Current Trend Analysis Report From Here

Clearwire Corporation (NASDAQ:CLWR) is slated to be acquired by its majority owner, Sprint, but not if a large shareholder group of Clearwire’s has anything to say about the matter. Not only has Crest Financial filed a class action lawsuit on behalf of Clearwire investors, but it will also request that the United States Federal Communications Commission block Sprint’s intent to sell 70 percent of itself to Softbank Corp for $20 billion, which would greatly complicate Sprint’s plans for Clearwire. Crest owns roughly 8 percent of the latter and has characterized Sprint’s offer of $2.97 per share for the approximate 50 percent of Clearwire it does not currently own, saying that it “grossly undervalues Clearwire.”

Will CLWR Investor Booked Profit From CLWR And Wait For Correction: Find Out Here

First Solar (NASDAQ:FSLR) was the worst performer in the group of 500, falling 6.6%. Down 11% in the last year, the volatile solar module manufacturer entered into a licensing deal with Intermolecular (NASDAQ: IMI ) today, attempting to increase the efficiency of its products. The agreement was a sobering reminder that solar power still has quite a way to go before becoming market-competitive with more traditional energy sources.

At Which Point Investor Book Profit From FSLR: FIND OUT HERE

Shares of robotic surgery device maker MAKO Surgical (NASDAQ:MAKO) fell as much as 14% following the release of select fourth-quarter earnings data -- although, shares have rebounded to be lower by only 4.5% as of this writing. MAKO is actually presenting at the JPMorgan Healthcare Conference on Wednesday and is widely expected to release its full-year results then. However, the data divulged today shows that MAKO sold 15 Robotic Arm Interactive Orthopedic systems, or RIOs, during the quarter, matching its total in the third quarter, and hitting the midpoint of its annual range of 42 to 48 systems. Also, MAKOplasty procedures rose by 20% over the sequential quarter to 2,904, and are 29% higher than the year-ago quarter.

Should Investor Book Profit Or Hold MAKO This Range: Check Out Here

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

Contact:
hotpennystocknews.com
info@hotpennystocknews.com